In refractory leukemia, IV busulfan plus cyclophosphamide may be a valid alternative
the ONA take:
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative to cyclophosphamide plus total body irradiation conditioning regimen for patients with refractory acute myeloid leukemia, according to a new study published online ahead of print in the The Lancet Haematology.
For the study, researchers analyzed data from 514 patients with refractory acute myeloid leukemia in active phase who had received intravenous busulfan plus cyclophosphamide and 338 patients who had received cyclophosphamide plus total body irradiation. All patients then received allogenic hematopoietic stem-cell transplantation from an HLA-identical sibling or an unrelated donor.
Results showed that 2-year overall survival and 2-year leukemia-free survival did not differ between the 2 groups. Researchers found that the main reasons for non-relapse mortality were graft-versus-host disease and infection.
The findings suggest that intravenous busulfan plus cyclophosphamide may be especially preferable for transplant centers that do not have access to radiation facilities.
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative for patients with refractory acute myeloid leukemia.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|